process design for the production of fab fragment for therapy group 6 shiang-yuan hsieh, yun-hsuan...
TRANSCRIPT
Process design for the production of Fab fragment for therapy
Group 6Shiang-Yuan Hsieh, Yun-Hsuan Liu, Chao-Ming Yen
Bevacizumab v.s Ranibizumab
• Anti-angiogenic drugs: block the formation of new blood vessels to inhibit tumor growth
• By targeting and inhibiting the function of a natural protein called vascular endothelial growth factor (VEGF)
• The whole antibody versus a antibody fragment
Antibody• Also called immunoglobulins (Ig) that used by
immune system.• Five classes of Ig: IgA, IgE, IgG, IgD, IgM.
Fragment antigen binding(Fab fragment)
• A region on an antibody which binds to antigens
• Composed of one constant and one variable domain of each of the heavy and the light chain
Why make Fab Fragments?
• Smaller size that can promote the efficiency of penetration of tissue section.
• Reduce nonspecific binding that results from Fc interactions.
• Potentially higher sensitivity in antigen.• Reduce the risks from immune response.• Production is more economical.
Results of production reactor• 100 g dry weight of cells/L • Periplasm production of Fab fragments
– (50g /l protein, 3 g Fab/l)
This is the starting material of your separationYour product is in periplasmSo first step should be 1. Separation of cells by centrifugation/microfiltation2. loosely breakup cells
potentially use osmotic shock (high concentration of guanidine HCL or urea)
3. Ion exchange for enriching Fab fragment
Antibody Purification - Affinity Chromatography
1. Use the original VEGF as the antigens2. Other antigens (Gammabind G Sepharose) Barbas et al. (2001).
Antibody Purification - Use Device: Gradiflow